


High Incidence of Comorbidities in CWE: Population Study

- Norwegian Patient Registry between 2008-2013
- Children with epilepsy (CWE) were compared to general child population (GCP)
- 6,635 children with epilepsy compared to 1,125,161 children

	CWE	GCP
>1 comorbid disorder	78.3%	30.3%
Developmental and/or psychiatric disorder	42.9%	6.6%
Neurologic disorder	41.3	2.5%
Medical disorder	19.1%	5.4%

Category	CWE (N =	= 6635)	GCP ($N = 1$	125 161)	CWE vs GCP
Disorders	N	%	Ν	%	OR (99% CI)
Developmental/psychiatric disorders	2847	42.9	74 086	6.6	9.4 (8.7-10.0)*
Disorders of psychological development (including autism)	1414	21.3	21 787	1.9	11.6 (10.7-12.6)*
Autism	516	7.8	7104	0.6	10.7 (9.5-12.1)*
Intellectual disability	1126	17.0	4583	0.4	41.0 (37.3-45.0)*
ADHD	801	12.1	21 872	1.9	5.4 (4.8-5.9)*
Behavioral/emotional disorders (except ADHD)	698	10.5	28 941	2.6	3.6 (3.2-3.9)*
Unspecified developmental delay	494	7.5	11 834	1.1	8.2 (7.3–9.3)*
Anxiety	99	1.5	5463	0.5	2.3 (1.8-3.0)*
Depression	72	1.1	4873	0.4	1.8 (1.4-2.5)*
	Ameri	can Epilepsy	/ Society 20	24 Annual Mee	ting Los Angeles, CA #
1, Pediatrics 2016					5. 5.





High Incidence of Comorbidities in CWE: Preceding Medication Initiation


- Single-center retrospective chart review of 380 youths with epilepsy with completed Behavior Assessment System for Children – Parent Rating Scale (BASC-2:PRS) and Pediatric Epilepsy Side Effect Questionnaire (PESQ)
- Overall baseline elevated symptoms prior to ASM imitation
- Younger age and baseline hyperactivity were associated with increased levels of ASM behavioral side effects


- Independent of ASM


Guilfoyle SM, Epilepsia 2017











Hypothesized Behavior Mechanism in
Neurodevelopmental Disorders

Setting Event

Stomach

- Up to 40% of children with autism spectrum disorder have aggressive or selfinjurious behavior
- Proposed mechanisms:
 - Operant conditioning: Antecedent > Behavior > Consequence(s)
 - Provoking factor: Setting event > Antecedent > Behavior > Consequence
 - Interoception: Dysregulated processing of sensations such as pain/discomfort, hunger, thirst

Pain		on task
SettingInteroceptiveEventResponsivity	Antecedent Behavior	Consequence
Stomach > High > pain	Math task > Aggression >	Escapes working on math task
Stomach > Low > pain	Math task > No > aggression	 Works on math task
Stomach > Unable to > pain locate pain	Math task > Aggression >	Escapes working on math task
Stomach > Not > pain impaired	Math task > No > aggression	 Works on math task
American Epilepsy Socie	ty 2024 Annual Meeting	Los Angeles, CA #AES2024

Behavior

> Aggression >

Consequence

Escapes working


Antecedent

Math task


Edelson SM, Journal of Personalized Medicine 2022

American Epilepsy Society-Child Neurology Foundation Symposium at the 2024 AES Annual Meeting | December 6, 2024

ledical	Neurological	Developmental/psychiatric
astrointestinal disorders	Cerebral palsy	Autism spectrum disorder
utritional and bone health	Headache and migraines	Intellectual disability
learing and vision impairment	Neuropathic pain	ADHD
Sleep		Anxiety
letabolic disorders		Depression
nfectious causes		Sensory processing disorders
Dental		



at the 2024 AES Annual Meeting | December 6, 2024



Anti-seizure Medications Can Impact Sleep

Table 1. Effect of antiepileptic drugs on sleep.

	Effect on sleep					Effects on slee	Effects on sleep disorders			
	Sleep efficiency	Sleep latency	Stage I	Stage II	Stage III	REM	Improves/ treats	Worsens		
Phenobarbitone	1	Ļ	-	↑	0	Ļ	Sleep onset insomnia	OSA		
Phenytoin	0	Ļ	î	Î	Ļ	0 or ↓	None known	None known		
Carbamazepine	0	0	0	0	0	0	RLS	RLS		
Valproate	-	0	î	Ţ	0	0	None known	OSA*		
Ethosuximide	-	-	Ť	-	L	-	None known	None known		
Gabapentin	0	0	Ó	0	Ť	Ť	RLS	OSA*		
Lamotrigine	0	0*	0	↑	i	Ť	None known	None known		
Topiramate	0	L	0	Ó	Ó	Ó	OSA*	None known		
Tiagabine	-	-	-	-	1	-	Insomnia	None known		
Levetiracetam	-	-	-	-	1	-	None known	None known		
Pregabalin	Î	-	-	-	Ť	-	None known	OSA*		

0, no change; -, not reported; ↑, increase; ↓, reduction; OSA, obstructive sleep apnoea; REM, rapid eye movement; RLS, restless leg syndrome


*Due to change in weight


[†]Lamotrigine may be associated with insomnia (clinical observation but rarely reported in the literature)

American Epilepsy Society | 2024 Annual Meeting | Los Angeles, CA | #AES2024

https://epilepsysociety.org.uk/sites/default/files/2020-08/Chapter18Eriksson2015_0.pdf

American Epilepsy Society-Child Neurology Foundation Symposium at the 2024 AES Annual Meeting | December 6, 2024






Epilepsy Syndromes and Associated Cognitive and Psychiatric Impairments


	Corepathophysiology	Core cognitive deficit	Core psychiatric defici
Temporal lobe epilepsy	Hippocampus and mesial temporal lobe	Anterograde memory	Depression and anxiety
Frontal lobe epilepsy	Frontal lobe	Executive functions	Personality disorders
Benign epilepsy with centrotemporal spikes	Sylvian and Rolandic regions	Language abilities	Unknown
Absence epilepsy	Thalamocortical network	Attention	Unknown
Juvenile myoclonic epilepsy	Frontothalamic network	Executive functions	Personality disorders

Lin JJ, Lancet 2012





American Epilepsy Society | 2024 Annual Meeting | Los Angeles, CA | #AES2024







Durad	
Drug Barbiturates (primidone and	Psychiatric side effects Decression
phenobarbital)	In children and individuals with intellectual disabilities: hyperactivity, irritability, aggression
Benzodiazepines	In children, older adults, and individuals with intellectual disabilities: hyperactivity, irritability, aggression
Brivaracetam	Aggressive behavior, depression, psychosis, but better tolerated than levetiracetam
Carbamazepine	Not reported
Eslicarbazepine	Not reported
Ethosuximide	Psychosis
Felbamate	Anxiety, psychosis
Gabapentin	In children and individuals with intellectual disabilities: hyperactivity, aggression, irritability
Lacosamide	Not reported
Lamotrigine	In individuals with intellectual disabilities: hyperactivity, irritability, aggression
Levetiracetam	Irritability, aggression, anxiety, depression, psychosis
Oxcarbazepine	Not reported
Phenytoin	Psychosis (particularly at high serum levels)
Pregabalin	Depression
Rufinamide	Not reported
Stiripentol	Hyperactivity, irritability, aggression
Tiagabine	Irritability
Topiramate	Depression, psychosis, irritability
Valproate	Not reported
Vigabatrin	Psychosis, depression
	In children and individuals with intellectual disabilities: hyperactivity, aggression, agitation
Zonisamide	Psychosis, depression, irritability
	American Epilepsy Society 2024 Annual Meeting Los Angeles, C









Management Strategies

- Obtain baseline cognition, behavior and habits
- Use formal screening tools for accurate and timely diagnosis and for surveillance over time
- Identify externalizing and internalizing behaviors and associated triggers
- Identify and treat any reversible medical causes of behavioral worsening such as presence of migraines or difficulties with sleep
- Identify the epilepsy syndrome and/or the etiology for the epilepsy which may have associated behavioral or cognitive differences
- Behavioral therapy, cognitive-behavioral therapy (CBT), and family counseling (parent-child interactive therapy) can be very helpful for managing behavior

American Epilepsy Society | 2024 Annual Meeting | Los Angeles, CA | #AES2024 33

Take Away Messages

- Behavioral and psychiatric co-morbidities are common!
- Use a multi-disciplinary approach to screen and appropriately diagnose behavioral and dysregulated emotions are key
- Treat any co-morbid conditions found that can exacerbate behaviors and seizures
- Behavioral interventions and supportive therapies can help manage comorbidities
- Medications for behaviors should be considered only if necessary

American Epilepsy Society | 2024 Annual Meeting | Los Angeles, CA | #AES2024

References

- Aaberg KM, Bakken IJ, Lossius MI, et al. Comorbidity and childhood epilepsy: a nationwide registry study. Pediatrics 2016. 138(3):e20160921.
- Anto M, Shipley SC, Massey S, Szperka C. Adverse childhood experiences are associated with seizures in children. Neurology Clinical Practice 2023. 13(2): e200136.
- Austin J, Harezlak J, Dunn D, et al. Behavior problems in children before first recognized seizures. Pediatrics 2001. 107: 115–22.
- Berg AT, Altalib HH, Devinsky O. Psychiatric and behavioral comorbidities in epilepsy: a critical reappraisal. Epilepsia 2017. 58(7):1123-1130.
- Chen B, Choi H, Hirsch LJ et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behavior 2017. 27:24-31.
- Dunn DW, Austin JK. Behavioral issues in pediatric epilepsy. Neurology. 1999.53:S96-100.
- Dunn D, Austin J, Huster G. Behaviour problems in children with new onset epilepsy. Seizure 1997. 6: 283-7.
- Edelson SM. Understanding challenging behaviors in autism spectrum disorder: a multi-component, interdisciplinary model. Journal of Personalized Medicine 2022: 12(7).1127.
- https://epilepsysociety.org.uk/sites/default/files/2020-08/Chapter18Eriksson2015_0.pdf
- Guilfoyle SM, Follansbee-Junger KF, Smith AW. Antiepileptic drug behavioral side effects and baseline hyperactivity in children and adolescents with new onset epilepsy. Epilepsia 2017. 59(1): 145-154
- Hesdorffer DC, Ishihara L, Mynepalli L et al. Epilepsy, suicidality, and psychiatric disorders: A bidirectional association. Annals of Neurology 2012. 72(2):184-91.
- Kelley SA, Hartman AL, Kossoff EH. Comorbidity of migraine in children presenting with epilepsy to a tertiary care center. Neurology 2012.79(5):468-73.
- Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 2012. 380. 1180-1192.
- Mula M, Coleman H, Wilson SJ. Neuropsychiatric and cognitive comorbidities in epilepsy. Continuum 2022. 28(2):457-482.
- Oakley CB, Kossof EH. Migraine and epilepsy in the pediatric population. Current Pain and Headache Reports 2014.18(3):402.
- · Oh A, Thurman DJ, Kim H. Comorbidities and risk factors associated with newly diagnosed epilepsy in the U.S. pediatric population. Epilepsy & Behavior 2017. 75:230-236
- Ott D, Siddarth P, Gurbani S et al. Behavioral disorders in pediatric epilepsy: unmet psychiatric need. Epilepsia 2003. 44(4):591-7.
- Oyegbile-Chidi T, Harvey D, Eisner J et al. The relationship between sleep, cognition, and behavior in children with newly diagnosed epilepsy over 36 months. Frontiers in Neurology 2022.13:903137.
- Reilly C, Atkinson P, Das KB, et al. Neurobehavioral comorbidities in children with active epilepsy: a population-based study. Pediatrics 2014. 133(6):e1586-93.
- Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies position paper of the ILAE commission for classification and terminology. Epilepsia 2018. 58(4):512-521.
- Scott AJ, Sharpe L, Hunt C, Gandy M. Anxiety and depressive disorders in people with epilepsy: a meta-analysis. Epilepsia 2017. 58(6):973-982.
- Sveinnson O, Andersson T, Mattsson P et al. Clinical risk factors in SUDEP: A nationwide population-based case-control study. Neurology 2020;94:e419-e429.
- von Wrede R, Witt JA, Jessen N et al. Screening for depression in patients with epilepsy: What are the benefits for physicians and patients in the real-life setting. Epilepsia 2024. 00:1-7.
- Watkins LV, Pickrell WO, Kerr MP. Treatment of psychiatric comorbidities in patients with epilepsy and intellectual disabilities: Is there a role for the neurologist? Epilepsy & Behavior 2019. 98:322-327.

American Epilepsy Society | 2024 Annual Meeting | Los Angeles, CA | #AES2024



American Epilepsy Society-Child Neurology Foundation Symposium at the 2024 AES Annual Meeting | December 6, 2024